Saint-Malo - CH
Welcome,         Profile    Billing    Logout  
 1 Trial 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
MOREL, Hugues
PROMETHEE, NCT06646471: PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly With Thoracic Malignancies

Recruiting
4
500
Europe
Bio-bank repository, Quality of Life (QoL), G-Code
Groupe Francais De Pneumo-Cancerologie
Non Small Cell Lung Cancer, Lung Cancer
08/26
08/28
DIAL, NCT05255302 / 2021-006044-27: De-escalation Immunotherapy MAintenance Duration Trial for Stage IV Lung Cancer Patients with Disease Control After Chemo-immunotherapy Induction

Recruiting
2/3
1360
Europe
Pembrolizumab before randomization, Chemotherapy, Pemetrexed, Pembrolizumab after randomization
Intergroupe Francophone de Cancerologie Thoracique, IFCT
Metastatic NSCLC
01/25
06/29
GFPC 06-2018, NCT04042558 / 2019-000727-41: A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies

Recruiting
2
149
Europe
Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab, Carboplatin + Pemetrexed + Atezolizumab
Centre Francois Baclesse, GFPC
NSCLC Stage IIIB, NSCLC Stage IV, EGFR Gene Mutation, ALK Gene Rearrangement Positive, ROS1 Gene Mutation
10/21
06/25
ORBITAL, NCT04233021: Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation

Active, not recruiting
2
57
Europe
Osimertinib
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer Metastatic, Leptomeningeal Metastasis, Brain Metastases, EGFR Activating Mutation
03/23
12/24
ORAKLE, NCT04111705: Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients with Advanced ALK-positive Non-small Cell Lung Cancer

Active, not recruiting
2
23
Europe
Lorlatinib
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer Metastatic
01/25
01/25
AKAPI, NCT06585020: Amikacin Liposome Inhalation Suspension for Treatment of Mycobacterium Xenopi Pulmonary Infection

Not yet recruiting
2
190
Europe
Arikayce, standard treatment
Centre Hospitalier Universitaire, Amiens, University Hospital, Angers, Hospital Avicenne, University Hospital, Bordeaux, University Hospital, Brest, CH Compiègne, Créteil Hospital, Centre Hospitalier Universitaire Dijon, University Hospital, Grenoble, Centre Hospitalier le Mans, Hôpital de la Croix-Rousse, APHM - Nord, Hôpital Saint Joseph, CH Mulhouse, CH Orléans, Tenon Hospital, Paris, Hôpital Necker-Enfants Malades, CH PERPIGNAN, Poitiers University Hospital, CH Pontoise, CHU de Reims, Rennes University Hospital, CHU de Rouen - Accueil, Central Hospital Saint Quentin, IHU Strasbourg, University Hospital, Tours, CH Abbeville, CH Cannes
Mycobacterium; Xenopi, Lung Diseases
08/26
08/27
OBSTINATE, NCT05049044: Observational Prospective Study of Quality of Life in Unresectable TNM Stage III NSCLC

Active, not recruiting
N/A
413
Europe
Quality of Life Questionnaire-Core 30 (QLQ-C30), Quality of Life Questionnaire-Lung Cancer 13 (QLQ-LC13), 5-level EuroQoL EQ5D (EQ5D-5L)
Groupe Francais De Pneumo-Cancerologie, AstraZeneca
Non-Small Cell Lung Cancer
06/27
06/27
BIOEXALK, NCT05122806: Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC

Recruiting
N/A
100
Europe
RNAseq, DNA NGS
Groupe Francais De Pneumo-Cancerologie, Takeda
Non-small Cell Lung Cancer, ALK Gene Rearrangement Positive
06/27
06/27
ROSIE, NCT06053099: A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)

Recruiting
N/A
300
Europe
Plasma ctDNA, FFPE blocks
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer, EGFR Activating Mutation, EGFR DEL19, EGFR L858R
10/31
10/31

Download Options